Ever Supreme Bio Technology Co., Ltd Reports Earnings Results for the Second Quarter Ended June 30, 2021
August 11, 2021 at 05:12 pm EDT
Share
Ever Supreme Bio Technology Co. Ltd. announced earnings results for the second quarter ended June 30, 2021. For the second quarter, the company announced sales was TWD 91.048 million compared to TWD 9.619 million a year ago. Operating income was TWD 20.007 million compared to operating loss of TWD 47.674 million a year ago. Net income was TWD 67.688 million compared to net loss of TWD 41.074 million a year ago. Basic earnings per share from continuing operations was TWD 1.1 compared to basic loss per share from continuing operations of TWD 0.73 a year ago. Diluted earnings per share from continuing operations was TWD 1.09 compared to diluted loss per share from continuing operations of TWD 0.73 a year ago. For the half year, sales was TWD 140.040 million compared to TWD 17.381 million a year ago. Operating income was TWD 5.941 million compared to operating loss of TWD 81.313 million a year ago. Net income was TWD 54.247 million compared to net loss of TWD 67.135 million a year ago. Basic earnings per share from continuing operations was TWD 0.88 compared to basic loss per share from continuing operations of TWD 1.2 a year ago. Diluted earnings per share from continuing operations was TWD 0.87 compared to diluted loss per share from continuing operations of TWD 1.2 a year ago.
Ever Supreme Bio Technology Co., Ltd. is a Taiwan-based company mainly engaged in the research, design, development, manufacture and sales of stem cell products and immune cell products. The Company has three main products. ADCV01 is an autologous dendritic cell tumor vaccine product, which is currently in the phaseII of clinical trials in Taiwan. UMSC01 is a human allogeneic umbilical cord stem cell product and a new drug for the treatment of myocardial infarction, which is approved by the United States Food and Drug Administration (FDA) clinical phaseI and is currently applying for the phaseI of clinical trials in Taiwan. UMSC01 is a human allogeneic umbilical cord stem cell product, which is used to treat acute ischemic stroke and is currently in the United States FDA for clinical phase I. The Company plans to develop new products and services including mesenchymal stem cells for the treatment of multiple sclerosis.